ALSO NOTED: Canadian regulators warn on impotence drugs; ZARS wins FDA OK; MAP, Elan expand collaboration; and much more...

> Canadian regulators warn of potential vision problems from impotence drugs. Story

> ZARS nabs its first FDA approval for one of its products, the Synera anesthetic patch. Release

> MAP Pharmaceuticals and Elan have expanded their collaboration. Release

> FDA chief, critics clash in House hearings over agency budget. Story

> FDA taps Pfizer to pull Zyvox ad from professional journal. Report

> Swiss manufacturer Lonza sees first-half earnings raised by biopharma unit. Story

> Testosterone patch boosts women's drive but FDA still wants safety data. Report

> AutoGenomics, Targeted Molecular Diagnostics strike development partnership to identify cancer biomarkers to be used for personalized treatments. Release

> Geron starts testing its lead anti-cancer compound with two Phase I/II clinical trials. Release

> Chinese drug maker to supply ingredients to makers of generic anti-AIDS drugs to be distributed by Clinton Foundation in Africa and Asia. Report

And Finally... Giveaway program, advertising guidelines improve drug industry's tarnished image. Feature

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.